A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability and the Effect of Food on VH4524184 Tablet Formulations, and to Evaluate the Potential for VH4524184 Drug-Drug-Interactions in Healthy Adult Participants
Abstract
The aim of the study is to gather information on how the drug behaves in healthy adults, how it is absorbed, and how it interacts when taken with other medicines.
Conditions: HIV Infections.
Primary outcome: Part 1: Maximum plasma concentration (Cmax) for VH4524184; Part 1: Area under the concentration-time curve from 0 to tau (AUC0-t) for VH4524184; Part 1: Area under the concentration-time curve from 0 to infinity (AUC0-inf) for VH4524184; Part 2: Cmax for VH4524184; Part 2: AUC0-t of VH4524184; Part 2: AUC0-inf of VH4524184; Part 2: Cmax for metformin; Part 2: AUC0-t for metformin; Part 2: Cmax for Digoxin; Part 2: AUC0-t for Digoxin.
Enrollment: 126 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 126 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.